uniQure (NASDAQ:QURE) Trading Up 6.5% – Here’s Why

23 Feb 2026, 18:44 by Teresa Graham · The Cerbat Gem

uniQure N.V. (NASDAQ:QURE – Get Free Report)’s share price was up 6.5% during mid-day trading on Monday . The stock traded as high as $24.66 and last traded at $24.96. Approximately 1,082,899 shares were traded during trading, a decline of 43% from the average daily volume of 1,904,691 shares. The stock had previously closed at $23.43.

Wall Street Analyst Weigh In

QURE has been the topic of a number of analyst reports. The Goldman Sachs Group reduced their price objective on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 4th. Leerink Partners dropped their target price on shares of uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Benchmark reiterated a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. Wolfe Research started coverage on uniQure in a research report on Monday. They issued a “peer perform” rating for the company. Finally, Chardan Capital reissued a “buy” rating and issued a $53.00 price objective on shares of uniQure in a research note on Thursday, December 4th. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and an average price target of $58.33.

Check Out Our Latest Analysis on uniQure

uniQure Stock Performance

The firm has a market cap of $1.52 billion, a P/E ratio of -5.57 and a beta of 0.66. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. The company’s 50-day moving average is $23.60 and its two-hundred day moving average is $29.55.

Insider Activity at uniQure

In related news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director owned 20,439 shares in the company, valued at approximately $557,575.92. This represents a 23.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Robert Gut sold 25,613 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares of the company’s stock, valued at $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.79% of the stock is owned by insiders.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently modified their holdings of the business. Swiss National Bank bought a new position in uniQure in the 2nd quarter worth approximately $1,080,000. Sanders Morris Harris LLC purchased a new position in uniQure during the 3rd quarter valued at about $5,081,000. Jennison Associates LLC bought a new stake in shares of uniQure during the second quarter valued at about $1,952,000. JPMorgan Chase & Co. increased its position in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after buying an additional 1,491,486 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of uniQure in the second quarter worth about $872,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.